Navigation Links
'Best CRO' Award Recognizes Accelovance's Support of Vaccine Development
Date:4/30/2009

ROCKVILLE, Md., April 30 /PRNewswire/ -- Accelovance, a privately held vaccine-focused clinical research company, announced today it received the Vaccine Industry Excellence (ViE) award as "Best Contract Research Organization" (CRO) at the 2009 World Vaccine Congress, held recently in Chantilly, VA.

The ViE awards were established to generate public recognition of the efforts, accomplishments, and positive contributions of organizations and individuals in the global vaccine industry. The "Best CRO" award is designed to highlight the importance of contract research services within the vaccine industry. It identifies Accelovance as best-in-class for services that advance vaccine development.

"There is obviously tremendous pride with this award. It reflects our commitment to excellence and focus on the niche market of vaccines," commented Steve Trevisan, President and CEO of Accelovance. "This award recognizes how we have served clients, both large and small, across all stages of clinical development by providing solutions to their needs or challenges. We will continue to focus on our clients and our mission of bringing innovation, operational efficiencies and high quality performance at multiple levels through our offering of CRO, Clinical Sites, Patient Recruitment and Clinical Call Center services."

A panel of international judges reviews nominations to determine each year's recipients of the ViE awards. In 2008, Accelovance was a finalist in the same category of "Best CRO."

Headquartered in Rockville, Maryland, Accelovance is a privately held company that has developed a unique operational approach for delivering quality, on time, and cost-effective clinical studies. Accelovance offers seven (7) wholly-owned, research-dedicated clinical sites to Sponsors and CROs that bring greater control, predictability, and quality assurance to vaccine programs. Additionally, the Company tailors its offering of full CRO, Clinical Sites, Patient Recruitment, and Call Center to present a clinical solution that meets a Sponsor's needs. Accelovance has a 100% owned subsidiary providing CRO services in China. These capabilities can assist clients with global development programs or product registration in China, the fastest growing pharmaceutical market in the world.

For more information, visit the company's website at http://www.accelovance.com.

    Media Contact:
    Garrett D. Smith
    Phone: 240.238.4900
    gsmith@accelovance.com


'/>"/>
SOURCE Accelovance
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. The Pharma & Life Sciences Best Practice Database: an Industry Resource for Successful Techniques and Performance Benchmarks for Reaching the Top
2. How Best to Treat Preschoolers With ADHD? The Harvard Mental Health Letter Discusses the Options
3. Consumer Reports Analysis: Drugs for Nerve Pain, Fibromyalgia Effective, But Not Always Best
4. Mothers Know Best: NFL Moms Team With Eddie George to Showcase a Better Way to a Healthier Lifestyle
5. Abaxis to Present at the CL King Best Ideas Conference 2007
6. Temple Emergency Medicine receives $1.8M to find best MRSA treatment
7. Multi-Year Compendium of Pharmaceutical Case Studies Available from Best Practices, LLC
8. Methadone and systematic follow-up: the best solution for managing chronic pain
9. Best Practice Database: Complimentary Excerpt of Three Sales Force Excellence Studies
10. GPS-like technology helps pinpoint best methods for moving injured players
11. Aerobic, Weight Training Combo Best Against Diabetes
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/26/2017)... ... April 26, 2017 , ... ... the adoption of e-prescribing as measured in Part D Medicare data. The dataset, ... to pharmacies, either using e-prescribing, faxes or paper. The PaPR (pronounced "paper") ...
(Date:4/26/2017)... ... 2017 , ... Infertility may be a result of an ... many women become pregnant upon treating their diagnosis. , To properly ... We can provide the necessary information to diagnose and treat your problem. ...
(Date:4/26/2017)... ... 26, 2017 , ... New SUPRO® XT55 Isolated Soy ... by helping beverage manufacturers more effectively manage protein costs. “Soy protein has always ... well as more stable pricing over time. Now it’s even more relevant as ...
(Date:4/25/2017)... ... April 25, 2017 , ... Splashtop Inc. , ... . This new addition to the Mirroring360 product family combines device screen mirroring ... Mirroring360 Pro enables educators, business professionals and individuals to stream or mirror app ...
(Date:4/25/2017)... (PRWEB) , ... April 25, 2017 , ... ... CEOs, CFOs and HR decision-makers are preparing for how his administration could impact ... will provide insight into what changes are most likely to make it through ...
Breaking Medicine News(10 mins):
(Date:4/19/2017)... 2017 Cardiology devices segment is anticipated to reach ... The Cardiology Devices segment is likely to create absolute $ ... 2018 over 2017. By the end of 2027, Cardiology Devices ... US$ 700 Mn, expanding at a CAGR of 18.4% over ... Asia Pacific reprocessed medical devices market in ...
(Date:4/19/2017)... , Tenn. and DALLAS , April ... EndoStim, Inc., announced that the first patients in ... the EndoStim device in the Lower Esophageal Sphincter Stimulation ... a minimally-invasive implantable device designed to provide long-term reflux ... neurostimulation. GERD affects nearly 65 million people ...
(Date:4/19/2017)... , April 19, 2017  Novartis today announced ... National Heart, Lung, and Blood Institute (NHLBI) of ... 58% of patients with treatment-naïve severe aplastic anemia ... treated with eltrombopag at the initiation of and ... study evaluated three sequential treatment groups, or cohorts. ...
Breaking Medicine Technology: